West Pharmaceutical Services (United States)
WST
$365.00
+2.76%
West Pharmaceutical Services is a Pennsylvania-based supplier to the pharmaceutical, biotechnology, and generic drug industries, manufacturing elastomer-based packaging components such as stoppers, seals, and plungers, along with nonglass containment solutions and auto-injectors for injectable drugs, including large-molecule biologics, GLP-1 peptides, and small-molecule therapies. The company operates through two segments — proprietary products (~80% of revenue) and contract-manufactured products (~20%) — and derives roughly 55% of revenue internationally, giving it a distinct position as a critical, high-specification component supplier embedded in the injectable drug supply chain rather than a commodity packaging vendor. The current investor narrative centers on West's leverage to the GLP-1 obesity and diabetes drug boom, which drove a significant Q1 2026 earnings beat and a raise in annual guidance, as highlighted in recent coverage. At the same time, debate persists around customer destocking dynamics in the broader medical supply space and whether West's premium valuation can be sustained if high-growth biologics demand normalizes.…
WST
West Pharmaceutical Services (United States)
$365.00
Related headlines
Investment Opinion: Should I buy WST Today?
The synthesized recommendation is Buy, anchored by a unanimous strong_buy analyst consensus (mean 1.41 from 16 analysts) and an average target price of $405.38, implying 17.1% upside from $346.23. The core thesis is that West Pharmaceutical is a high-quality, cash-generative supplier with a durable competitive moat in injectable drug packaging, leveraged to the secular GLP-1 growth wave, and its premium valuation is justified by superior margins and returns. However, the stock is not cheap, and investors should expect volatility given its beta of 1.135 and recent 1-month decline of 1.72%.
Supporting evidence includes Q1 2026 revenue growth of 21.01% year-over-year to $844.9 million, net margin expansion to 16.43% from 12.86%, and a debt-to-equity ratio of just 0.131. The company generated $458.0 million in trailing twelve-month free cash flow and returned $297.6 million via buybacks in Q1 2026, demonstrating strong capital allocation. The forward PE of 34.70x is below the trailing PE of 40.28x, reflecting expected EPS growth to $13.71, and while the PEG ratio of 33.99x is elevated, it is partly a function of the company's high-quality earnings and GLP-1 optionality. Relative to its own history, the current PE is below the 45–63x range seen in 2024 and early 2025, suggesting the valuation is not at an extreme.
The biggest risks that could invalidate the thesis are a sharper-than-expected deceleration in GLP-1 demand, customer destocking similar to what impacted CooperCompanies, and multiple compression if interest rates remain elevated. The rating would upgrade to a stronger Buy if the stock breaks above $386 on accelerating revenue growth, or downgrade to Hold if revenue growth falls below 15% or if gross margin declines below 34%. At 40.28x trailing earnings and 6.47x sales, the stock is fairly valued to slightly overvalued relative to its recent history, but the premium is supported by its growth trajectory and market leadership. This is an objective, data-driven assessment, not personalized financial advice.
Sign up to view all
WST 12-Month Price Forecast
West Pharmaceutical presents a compelling growth story anchored by GLP-1 demand, with strong revenue growth, expanding margins, and a fortress balance sheet. The unanimous strong_buy consensus and 17.1% average upside to analyst targets support a bullish stance, though the premium valuation and recent momentum deceleration warrant medium confidence. The key tension is whether the company can sustain 20%+ growth to justify its 34.70x forward PE, or whether destocking and normalization will trigger multiple compression. I would upgrade to high confidence if the stock breaks above $386 on strong volume and Q2 earnings confirm accelerating demand; I would downgrade to neutral if revenue growth falls below 15% or if gross margin declines below 34%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $405.38 and implied upside of +11.1% versus the current price.
Average Target
$405.38
0 analysts
Implied Upside
+11.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$340 - $459
Analyst target range
West Pharmaceutical is covered by 16 analysts, with a consensus recommendation of "strong_buy" and a recommendation mean of 1.41 (where 1.0 is a strong buy and 5.0 is a sell), indicating a strongly bullish consensus. The average target price is $405.38, which implies approximately 17.1% upside from the current price of $346.23. The consensus EPS estimate averages $13.71, with a tight range of $13.44 to $14.03, and estimated revenue averages $4.42 billion, suggesting analysts expect continued top-line and bottom-line growth. The bullish consensus is reinforced by recent institutional actions, including Barclays upgrading to Overweight from Equal Weight in June 2026 and multiple firms maintaining Outperform or Overweight ratings through mid-2026. The target price range spans from a low of $340.00 to a high of $459.00, a spread of $119.00, or roughly 35% of the current price, which signals meaningful dispersion in analyst views. The high target of $459.00 implies roughly 32.6% upside and likely assumes accelerating GLP-1-driven demand, successful capacity expansion, and potential multiple expansion as West captures a larger share of the injectable drug packaging market. The low target of $340.00, just 1.8% below the current price, suggests a more conservative view that may price in margin compression, customer destocking headwinds, or slower-than-expected adoption of new biologic therapies. The wide spread between the low and high targets indicates elevated uncertainty around the durability of West's growth trajectory, though the strong_buy consensus and recent analyst upgrades suggest the balance of opinion remains firmly positive.
Bulls vs Bears: WST Investment Factors
The bull case currently has stronger evidence, supported by 21% revenue growth, expanding margins, a fortress balance sheet, and a unanimous strong_buy analyst consensus with 17.1% average upside. However, the bear case is not without merit: the PEG ratio of 33.99x and forward PE of 34.70x indicate the stock is priced for sustained high growth, leaving little room for disappointment. The most important tension is whether GLP-1-driven demand can continue to accelerate at a pace that justifies the premium multiple, or whether customer destocking and normalization in biologics demand will cause a valuation reset. Near-term price action—down 1.72% over the past month despite strong fundamentals—suggests the market is already debating this point. A breakout above $386 would confirm the bull thesis, while a breakdown below $330 could trigger a deeper retracement toward $300.
Bullish
- GLP-1 demand drives 21% revenue growth: Q1 2026 revenue of $844.9 million grew 21.01% year-over-year from $698.2 million, marking four consecutive quarters of sequential expansion. The proprietary products segment, at $694.3 million, is the primary beneficiary of the GLP-1 obesity and diabetes drug boom, which management cited when raising annual guidance.
- Margin expansion and robust profitability: Net margin expanded to 16.43% in Q1 2026 from 12.86% a year earlier, while operating margin reached 20.96% and EBITDA margin was 25.86%. This demonstrates strong operating leverage as revenue scales, with net income rising to $138.8 million from $89.8 million.
- Fortress balance sheet with minimal leverage: Debt-to-equity is just 0.131 and the current ratio is 3.02, providing ample liquidity and strategic flexibility. The company generated $458.0 million in trailing twelve-month free cash flow and returned $297.6 million via buybacks and $15.8 million in dividends in Q1 2026 alone.
- Strong analyst consensus and upside: All 16 covering analysts rate the stock a 'strong_buy' with a mean recommendation of 1.41, and the average target price of $405.38 implies 17.1% upside from $346.23. Barclays upgraded to Overweight in June 2026, reinforcing positive sentiment.
Bearish
- Extreme valuation leaves no margin for error: The trailing PE of 40.28x and forward PE of 34.70x are rich, while the PEG ratio of 33.99x is extraordinarily elevated, suggesting the stock is priced for perfection. EV/EBITDA of 26.97x and PS of 6.47x are also premium multiples that could compress sharply if growth decelerates.
- Recent momentum deceleration and distribution risk: The stock is down 1.72% over the past month, underperforming SPY by 0.66 percentage points, and has stalled below its 52-week high of $386.00. This divergence from the strong 6-month trend could signal early distribution or a consolidation phase that precedes a deeper pullback.
- Customer destocking headwinds in medtech: Recent news highlighted CooperCompanies' Q3 revenue miss due to U.S. inventory destocking, sending its shares down 16% after-hours. While West is not directly implicated, the broader medical supply sector faces similar destocking risks that could pressure West's order patterns.
- High beta amplifies downside in risk-off markets: With a beta of 1.135, West is 13.5% more volatile than the broader market, and its maximum drawdown over the period was -24.83%. In a market correction or sector rotation away from high-multiple healthcare, the stock could fall disproportionately.
WST Technical Analysis
West Pharmaceutical is in a sustained uptrend, with the stock up 31.28% over the past year and 25.26% year-to-date, though it remains 10.3% below its 52-week high of $386.00. At the current price of $346.23, the stock is trading at approximately 75.5% of its 52-week range (low of $223.83 to high of $386.00), positioning it in the upper quartile of its annual range — a sign of persistent momentum but also leaving room before overextension. The 6-month gain of 47.04% underscores the strength of the recovery from earlier lows, suggesting the market has rewarded the GLP-1-driven growth narrative. Near-term momentum has cooled, with the stock down 1.72% over the past month versus a 5.29% gain over three months, indicating a deceleration or consolidation phase after a strong run. This 1-month pullback diverges from the robust 1-year and 6-month trends, which could signal either a healthy pause before continuation or early distribution; notably, the stock has outperformed SPY by 15.06 percentage points over one year but underperformed by 0.66 points over the past month. The relative strength figures show WST's 6-month outperformance of 31.64 points against SPY, confirming that the medium-term trend remains decisively bullish despite the recent stall. Key technical support sits near the 52-week low of $223.83, with a more immediate support zone around the $330–$337 area where the stock has recently found buyers. Resistance is defined by the 52-week high of $386.00; a breakout above that level would signal a resumption of the primary uptrend and likely attract momentum capital, while a breakdown below $330 could open the door to a deeper retracement toward the $300 handle. With a beta of 1.135, West is roughly 13.5% more volatile than the broader market, meaning position sizing should account for amplified moves relative to SPY; the maximum drawdown of -24.83% over the period further illustrates the stock's capacity for sharp corrections.
Beta
1.14
1.14x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$224-$386
Price range past year
Annual Return
+41.7%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | +4.5% | -2.4% |
| 3m | +12.8% | +2.2% |
| 6m | +51.9% | +14.8% |
| 1y | +41.7% | +14.6% |
| ytd | +32.1% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
West's revenue trajectory remains solidly growth-oriented, with Q1 2026 revenue of $844.9 million representing 21.01% year-over-year growth from $698.2 million in Q1 2025. The sequential trend is also positive: revenue rose from $766.2 million in Q2 2025 to $804.3 million in Q3 2025, $805.0 million in Q4 2025, and then to $844.9 million in Q1 2026, marking four consecutive quarters of sequential expansion. The proprietary products segment, at $694.3 million, is the dominant revenue driver, consistent with its ~80% contribution to the total, and the GLP-1 demand wave appears to be a key catalyst behind the acceleration. This growth profile supports a premium multiple but also raises the bar for future quarters, as any deceleration in biologic or GLP-1-related demand could pressure the stock's valuation. Profitability is robust, with Q1 2026 net income of $138.8 million and a net margin of 16.43%, up from 12.86% in Q1 2025, reflecting meaningful margin expansion. Gross margin stood at 35.08% in Q1 2026, down slightly from 37.75% in Q4 2025 but above the 33.33% recorded in Q1 2025, indicating a generally improving trend despite quarterly volatility. Operating margin was 20.96% in Q1 2026, and EBITDA came in at $218.5 million with an EBITDA ratio of 25.86%, underscoring the company's ability to convert revenue into cash earnings at scale. The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.131 and a current ratio of 3.02, indicating ample liquidity and minimal leverage. Free cash flow on a trailing twelve-month basis was $458.0 million, and Q1 2026 free cash flow was $47.2 million, impacted by $42.7 million in capital expenditures and a $102.9 million working capital outflow. Return on equity was 15.54% and return on assets 11.38%, both healthy for a capital-intensive medical supplier. The company returned capital aggressively in Q1 2026, repurchasing $297.6 million of stock while paying $15.8 million in dividends, funded from a cash balance of $521.4 million — demonstrating confidence in its cash generation and commitment to shareholder returns.
Quarterly Revenue
$844900000.0B
2026-03
Revenue YoY Growth
+21.0%
YoY Comparison
Gross Margin
35.1%
Latest Quarter
Free Cash Flow
$458000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Because West Pharmaceutical is profitable, with Q1 2026 net income of $138.8 million and trailing EPS of $0.0248 (reflecting a data quirk likely tied to a specific reporting basis), the PE ratio is the appropriate primary metric. The trailing PE stands at 40.28x, while the forward PE is 34.70x, implying the market expects meaningful earnings growth over the next twelve months — the 13.9% compression from trailing to forward multiple signals that analysts anticipate EPS expansion to roughly $13.71 on average. The PEG ratio of 33.99x is extraordinarily elevated, suggesting that even after accounting for growth, the stock trades at a rich premium, which is a key risk consideration for valuation-sensitive investors. Against the broader medical instruments and supplies sector, West's PE of 40.28x and PS of 6.47x represent a premium, though the company's superior margins and GLP-1 exposure provide some justification. The EV/EBITDA of 26.97x and EV/Sales of 7.25x are also elevated, reflecting the market's willingness to pay up for West's quality and growth profile. The price-to-book ratio of 6.26x is high but consistent with the company's asset-light, high-return operating model and strong ROE of 15.54%. Relative to its own history, West's current PE of 40.28x is below the 45–63x range seen in 2024 and early 2025 but above the 30–34x levels observed in mid-2025, placing it in the middle-to-upper portion of its recent historical band. The PS ratio of 6.47x is notably below the 20–42x range recorded across 2024–2025, though this discrepancy likely reflects a change in share count or data methodology rather than a fundamental shift. Overall, the valuation appears to price in continued execution on the GLP-1 growth story, leaving limited margin for error if demand trends soften.
PE
40.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
West Pharmaceutical's financial risks are relatively contained given its low debt-to-equity of 0.131 and current ratio of 3.02, but the company's premium valuation depends on continued earnings growth. The trailing PE of 40.28x and forward PE of 34.70x imply that analysts expect EPS to expand to roughly $13.71, a 13.9% compression in multiple that requires execution. Any slowdown in revenue growth—which was 21.01% year-over-year in Q1 2026—could lead to multiple compression, especially with a PEG ratio of 33.99x that offers no valuation cushion. Additionally, Q1 2026 free cash flow was only $47.2 million, impacted by a $102.9 million working capital outflow, highlighting potential cash flow volatility despite strong trailing TTM FCF of $458.0 million.
Market and competitive risks are significant given West's premium positioning. The stock trades at a PS of 6.47x and EV/EBITDA of 26.97x, well above broader medical instruments and supplies sector averages, making it vulnerable to sector rotation if investors favor value over growth. The beta of 1.135 means West is 13.5% more volatile than the market, and its maximum drawdown of -24.83% illustrates the potential for sharp corrections. Recent news of destocking headwinds at CooperCompanies, which saw its stock drop 16% after a revenue miss, underscores that the medical supply sector is not immune to inventory corrections. Furthermore, West's 55% international revenue exposure introduces currency and geopolitical risks, particularly if global trade tensions escalate.
The worst-case scenario would involve a combination of decelerating GLP-1 demand, customer destocking, and multiple compression. If revenue growth slows to single digits and the forward PE compresses to the mid-20s—closer to the low end of its historical range—the stock could fall toward its 52-week low of $223.83, representing a 35.3% decline from the current price of $346.23. The analyst low target of $340.00 offers little downside protection, being only 1.8% below the current price, but a more severe scenario could see the stock test the $300 handle or lower if the 52-week low is breached. Given the maximum drawdown of -24.83% over the past period, a 25-35% correction from current levels is a realistic tail risk in a bear market for high-multiple healthcare stocks.
FAQ
The most severe risk is valuation compression: with a forward PE of 34.70x and PEG of 33.99x, any deceleration in growth could trigger a sharp de-rating, as seen in the maximum drawdown of -24.83%. Second, customer destocking in the medical supply sector, highlighted by CooperCompanies' recent revenue miss and 16% stock drop, could spread to West and pressure order patterns. Third, competitive and regulatory risks exist, including potential pricing pressure from large pharmaceutical customers and changes in healthcare regulations across its 55% international revenue base. Fourth, macro sensitivity is a concern given the beta of 1.135, meaning West is 13.5% more volatile than the market, and rising interest rates could disproportionately impact high-multiple healthcare stocks. These risks are ranked by severity, with valuation compression and destocking being the most immediate threats.
The 12-month forecast includes three scenarios: a bull case with 30% probability targeting $405–$459 (analyst high), a base case with 50% probability targeting $380–$410 (analyst average of $405.38), and a bear case with 20% probability targeting $300–$340 (analyst low of $340). The base case is most likely, assuming revenue growth moderates to 15-18% and margins remain stable, delivering approximately 17% upside. The bull case requires accelerating GLP-1 demand and a breakout above $386, while the bear case assumes destocking and multiple compression. Key assumptions include continued strong demand for injectable drug packaging, no major competitive disruptions, and a stable interest rate environment. The wide analyst target range of $340 to $459 reflects significant uncertainty, but the strong_buy consensus tilts the risk/reward positively.
WST appears fairly valued to slightly overvalued relative to its own history and the broader medical instruments sector. The trailing PE of 40.28x is below the 45–63x range seen in 2024 and early 2025, but above the 30–34x levels observed in mid-2025, placing it in the middle-to-upper portion of its recent band. The forward PE of 34.70x implies expected EPS growth to $13.71, and the PEG ratio of 33.99x is extraordinarily elevated, suggesting the market is paying a significant premium for growth. Compared to peers, the PS of 6.47x and EV/EBITDA of 26.97x are premium multiples, justified by West's superior margins and GLP-1 exposure. The market appears to expect continued high-teens to low-20s revenue growth and further margin expansion; any deviation could lead to multiple compression. Overall, the valuation is rich but not unreasonable given the company's quality and growth trajectory.
From a risk/reward perspective, WST offers a favorable setup for growth-oriented investors, with 17.1% upside to the average analyst target of $405.38 and a unanimous strong_buy consensus. The company's 21.01% revenue growth and expanding net margin of 16.43% demonstrate strong fundamental momentum, while the low debt-to-equity of 0.131 provides downside protection. However, the premium valuation—40.28x trailing PE and 33.99x PEG—means the stock is priced for continued execution, and any slowdown could lead to significant multiple compression. The biggest downside risk is a retest of the 52-week low of $223.83, representing a 35% decline, if GLP-1 demand normalizes or destocking spreads. Therefore, WST is a good buy for investors with a medium-to-long-term horizon who can tolerate volatility and believe in the durability of the GLP-1 growth story, but it may not be suitable for value-oriented or short-term traders.
WST is best suited for long-term investment, with a suggested minimum holding period of 2-3 years, given its growth stage, premium valuation, and the multi-year secular tailwind from GLP-1 drugs and biologics. The company pays a modest dividend with a yield of 0.31% and a payout ratio of 12.4%, indicating a focus on reinvestment and buybacks rather than income. The beta of 1.135 and maximum drawdown of -24.83% suggest that short-term trading carries significant volatility risk, and the stock's 1-month decline of 1.72% despite strong fundamentals illustrates the potential for near-term noise. Earnings visibility is relatively high due to long-term contracts with pharmaceutical customers, but quarterly fluctuations can be sharp. Therefore, investors should focus on the long-term growth trajectory rather than short-term price movements, and consider accumulating on pullbacks toward support levels.